Table 2. Randomized trials evaluating external beam radiation therapy dose escalation for localized prostate cancer.

Study	Patients	Dose (Gy)	Median follow-up (months)	bDFS	Grade 2+ GI toxicity
MD Anderson	301	78 vs. 70	104	78% vs. 59%*	26% vs. 13%*
PROG 95-09	393	79.2 vs. 70.2	107	83% vs. 68%*	24% vs. 13%
MRC RT01	843	74 vs. 64	120	55% vs. 43%*	33% vs. 24%*
GETUG 06	306	80 vs. 70	61	72% vs. 61%*	20% vs. 14%
Dutch CKVO96-10	669	78 vs. 68	70	54% vs. 47%*	35% vs. 25%*

*, P<0.05. bDFS, biochemical disease-free survival; GI, gastrointestinal.